Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: A double-blind, randomized, placebo-controlled trial

British Journal of Dermatology

Volumn 152, Issue 2, 2005, Pages 334-341

  Stainer, R ^a   Matthews, S ^a   Arshad, S H ^a   McDonald, S ^b   Robinson, J ^b   Schapira, C ^c   Foote, K D ^c   Baird Snell, M ^d   Gregory, T ^d   Pollock, I ^d   Stevens, M T ^e   Edwards, A M ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Crosby Clinical Research Centre   (United Kingdom)

^c ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^d CHASE FARM HOSPITAL   (United Kingdom)

^e EMStat Ltd   (United Kingdom)

Author keywords

Atopic dermatitis; Children; Double blind, placebo; Randomized controlled trial; Sodium cromoglicate

Indexed keywords

ALTODERM; CROMOGLYCATE DISODIUM; EMOLLIENT AGENT; MOMETASONE FUROATE; PLACEBO; STEROID;

ANALYSIS OF VARIANCE; ANALYTIC METHOD; AQUEOUS SOLUTION; ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG USE; ECZEMA; ERYTHEMA; FEMALE; HUMAN; INSOMNIA; LOTION; MALE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PARENTAL BEHAVIOR; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECORDING; SCORING SYSTEM; SENSORY DYSFUNCTION; SKIN; SKIN IRRITATION; STATISTICAL SIGNIFICANCE; STEROID THERAPY; STINGING SENSATION; TOPICAL TREATMENT;

ADMINISTRATION, CUTANEOUS; CHILD; CHILD, PRESCHOOL; CROMOLYN SODIUM; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MALE; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20044368631     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06303.x     Document Type: Article

References (32)

1. Schultz LF, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34:760-4.
2. Pierard GE, Pierard-Franchimont C, Ben Mosbah T et al. Adverse effects of topical corticosteroids. Acta Derm Venereol (Stockh) 1989; 151 (Suppl.):26-30.
3. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (Suppl. 1):S58-64.
4. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003; 111:1153-68.
5. Kimata H, Igarashi M. Topical cromolyn (disodium cromoglycate) solution in the treatment of young children with atopic dermatitis. Clin Exp Allergy 1990; 20:281-3.
6. Kimata H, Hiratsuka S. Effect of topical cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral anti-allergic medication, oxatomide. Eur J Pediatr 1994; 153:66-71.
7. Hiratsuka S, Yoshida A, Ishioka C et al. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol 1996; 98:107-13.
8. Nagano T. Topical use of disodium cromoglycate nebulizer solution in adults with severe atopic dermatitis. Allergy Prac 1987; 7:790-3.
9. Moore C, Ehlayel MS, Junprasert J et al. Topical sodium cromoglycate in the treatment of moderate-to-severe atopic dermatitis. Ann Allergy Asthma Immunol 1998; 81:452-8.
10. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186:23-31.
11. Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131:383-96.
12. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial. First results of ETAC. Pediatr Allergy Immunol 1998; 9:116-24.
13. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195:10-19.
14. Valdivieso R, Subiza J, Varela-Losada S et al. Severe allergic conjunctivitis and chemosis caused by disodium cromoglycate. J Invest Allergol Clin Immunol 1998; 8:58-60.
15. Wass U, Plaschke P, Bjorkander J et al. Assay of specific IgE antibodies to disodium cromoglycate in serum from a patient with an immediate hypersensitivity reaction. J Allergy Clin Immunol 1988; 81:750-7.
16. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. BMJ 1977; i:1570-2.
17. Thirumoorthy T, Greaves MW. Disodium cromoglycate ointment in atopic eczema. BMJ 1978; ii:500-1.
18. Croner S, Fagerlund E, Kjellman NI et al. Sodium cromoglycate ointment in atopic eczema during childhood. Opusc Med 1981; 26:49-50.
19. Kjellman NI, Gustafsson IM. Topical sodium cromoglycate in atopic dermatitis. A disappointing but informative trial. Allergy 1986; 41:423-8.
20. Pike MG, Atherton DJ. Failure of a new topical sodium cromoglycate formulation to improve atopic dermatitis (letter). Eur J Pediatr 1988; 148:170.
21. Ariyanayagam M, Barlow TJ, Graham P et al. Topical sodium cromoglycate in the management of atopic eczema - a controlled trial. Br J Dermatol 1985; 112:343-8.
22. Holgate ST, Edwards AM. The chromones: cromolyn sodium and nedocromil sodium. In: Middleton's Allergy Principles and Practice (Franklin Adkinson N Jr, Yunginger JW, Busse WW et al., eds), 6th edn. Philadelphia: Mosby, 2003; 915-27.
23. Pearce CA, Greaves MW, Plummer VM, Yamamoto S. Effect of disodium cromoglycate on antigen-evoked histamine release from human skin. Clin Exp Immunol 1974; 17:437-40.
24. Clegg LS, Church MK, Holgate ST. Histamine secretion from human skin slices induced by anti-IgE and artificial secretagogues and the effects of sodium cromoglycate and salbutamol. Clin Allergy 1985; 15:321-8.
25. Okayama Y, Benyon RC, Rees PH et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992; 2:401-9.
26. Walsh LJ. Ultraviolet B irradiation of skin induces mast cell degranulation and release of tumour necrosis factor-alpha. Immunol Cell Biol 1995; 73:226-33.
27. Ting S, Zweiman B, Lavker RM. Cromolyn does not modulate human allergic skin reactions in vivo. J Allergy Clin Immunol 1983; 71:12-17.
28. van Bever HP, Stevens WJ. The effect of local application of disodium cromoglycate (DSCG) solution on skin prick tests. J Allergy Clin Immunol 1991; 1:226 (Abstract).
29. Kimata H, Igarashi M. Inhibition of human allergic skin reactions in vivo by pretreatment with cromolyn (disodium cromoglicate). Allergy 1990; 45:393-5.
30. Phillips TJ, Kanj LF, Washek D et al. Topical cromolyn can modify human allergic skin reactions. Allergy 1996; 51:198-9.
31. Crossman DC, Dashwood MR, Taylor GW et al. Sodium cromoglycate: evidence of tachykinin antagonist activity in the human skin. J Appl Physiol 1993; 75:167-72.
32. Ahluwalia P, McGill JI, Church MK. Nedocromil sodium inhibits histamine-induced itch and flare in human skin. Br J Pharmacol 2001; 132:613-16.